A Novel Tolerogenic Dendritic Cell Platform with the Potential to Present the Antigen FVIII to Induce Tolerance Against FVIII in Haemophilia A Patients

Time: 11:30 am
day: Day Two


  • Presentation of a novel and patented platform for generation of tolerogenic DCs
  • Hear how the tolerogenic DCs have a potential to induce regulatory T and to reduce antigen-specific T cell responses
  • Learn how tolerogenic DCs loaded with FVIII can be used to treat haemophilia A patients who developed inhibitors